Halozyme Therapeutics HALO AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's AFS securities?
- Halozyme Therapeutics (HALO) reported AFS securities of $0 in Q1 2026.
- How has Halozyme Therapeutics's AFS securities changed year-over-year?
- Halozyme Therapeutics's AFS securities decreased by 100.0% year-over-year, from $130.71M to $0.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.